Companies / Estuary Bio
Estuary Bio
United States
Estuary Bio is developing gene therapies to treat autosomal dominant polycystic kidney disease (ADPKD)
Estuary Bio, based in United States, has 5 investors on file, among them 4BIO Capital, GV and Pivotal Life Sciences. Its latest round on record is Series A, 16 Oct 2026. Its site was last checked 13 Nov 2026: site answers.
Funding
1 round on recordRound sizes and total raised are on Fundup AI, our sister product for funding data.
Investors
5 investors on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital | |
| Portfolio page | Venture capital | |
| Portfolio page | Venture capital | |
| Page + round | Venture capital | |
| Page + round | Corporate VC |
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Estuary Bio and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when 4BIO Capital adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/estuarybio.com/investors
# also
GET /v1/companies/estuarybio.com
GET /v1/companies/estuarybio.com/news